BiOS

Biotech Operations & Systems

Are you ready to scale — or will materials, release, and ownership blow up first?

A fixed-fee Operational Scale-Up Assessment for emerging biotechs. We map the gaps between process, materials, quality, facilities, and people — then tell you what to decide this quarter.

$4,500 · 10 business days · ~8–12 hours of your team's time

Check fit for the $4,500 assessment See a sample decision page

Where scale-up usually breaks — between functions, not inside one

Process

→

Materials

→

Equipment

→

Quality

→

Data

→

People

Process scale-up → material demand → supplier exposure → release specs → inventory → scheduling. BiOS connects the chain so leadership can decide.

The pattern

Science often outruns the operating system that has to carry it.

The hard constraints show up late — and usually between functions, not inside one: material lead times, QC/CMO release lag, suite capacity, unclear decision rights. A generic maturity checklist will not tell you what to freeze this quarter.

BiOS is built for that moment: make the interfaces visible, rank what matters, and hand leadership a bounded decision package — not an open-ended retainer.

The offer

Operational Scale-Up Assessment

For emerging biotech and life-science teams moving toward scale-up, manufacturing, or more mature operations. One fixed fee. One decision package. Clear exclusions so scope cannot drift.

Fixed fee

$4,500

Delivery

10 business days

Your time

~8–12 hours

Check fit for the $4,500 assessment Preview sample pages

Current → future operations map

How process, equipment, materials, quality, data, and ownership must evolve together for the next campaign or lot.

Ranked cross-functional gaps

The consequential interface failures — with why they matter now — not an exhaustive SOP audit.

Now / Next / Later roadmap

Sequenced actions and dependencies so you know what to decide this quarter before more spend.

What $4,500 looks like

A decision page you can act on — not a maturity scorecard.

Illustrative excerpt from the Operational Scale-Up Assessment (fictional company). This is the format buyers and connectors should forward.

BiOS

Operational Scale-Up Assessment

NovaCell Therapeutics

Excerpt · Executive Decision Summary

Confidential · Sample

1. Executive Decision Summary

NovaCell is moving a perfusion-based mAb process from development toward early clinical manufacturing readiness. Technical process definition is ahead of the operating system required to run it reliably: material planning, release interfaces, and ownership of cross-functional decisions remain underspecified.

Decision required this quarter

Prioritize a single “scale-up operating path” for the next 90 days—freeze the materials / release / scheduling interfaces before committing additional process characterization spend.

Priority	Finding	Why it matters	Suggested move
P0	Drug substance material demand model not linked to campaign calendar	Lead-time exposure on critical media/filters will slip first tox lot	Build a 2-campaign material risk register with dual-source flags
P0	QC release ownership unclear between NovaCell and CMO partner	Release lag becomes the de facto schedule constraint	Name a single release decision owner + SLA for CoA exceptions
P1	Equipment capacity model assumes ideal changeover	Suite utilization overstated by ~18% in draft plan	Re-baseline changeover + buffer prep window with MSAT + Ops

Full sample continues with Current→Future Operations Map, Gap & Risk Assessment, and Now/Next/Later roadmap (not shown).

Open full sample excerpt Check fit for the assessmentIllustrative sample for a fictional company. Not a real client engagement.

Related formats (not the current offer)

Adjacent assessment shapes we may use later. The paid wedge right now is the Scale-Up Assessment above.

Facility Risk Assessment

HelixForge Biologics

View excerpt →

Process Design Assessment

Aurelia BioWorks

View excerpt →

Capability Gap Assessment

Northwind Cell Systems

View excerpt →

How it works

From fit check to a decision package.

Fit conversation (20–30 min)

Confirm stage, urgency, and whether the $4,500 Scale-Up Assessment is the right wedge — or not.

Systems review

Map the interfaces that constrain your next lot or campaign: process, materials, quality, facilities, data, ownership.

Decision package in 10 days

Prioritized gaps, a current→future map, and a Now/Next/Later roadmap you can act on this quarter.

Not included by default: exhaustive SOP review, detailed engineering design, validation packages, or full implementation projects. Those are separate — and we will say no if they threaten the fixed fee.

Check fit for the $4,500 assessment

Founder

Lee Stevens

Chemical engineer with ~15 years across consulting and biotech operations — spanning process/MSAT, manufacturing, materials and supply chain, equipment and facilities, quality interfaces, automation, and the business decisions that keep those systems coherent.

BiOS exists to bring that systems lens to emerging companies that need a clear this-quarter decision — starting with a fixed-fee Operational Scale-Up Assessment — more than another open-ended retainer.

Check fit for the $4,500 assessment

Next step

Check fit for the $4,500 assessment.

Tell me your stage and the operational pressure you're under. If it's a fit, we scope the fixed-fee Scale-Up Assessment clearly before anything starts — 10 business days, ~8–12 hours of your team's time.

Prefer email directly: lee@biotechops.co

Or review the sample decision page first →